Instrument Inactif

Communiqués Accentia Biopharmaceuticals Inc

Actions

Recherche biotechnologique et médicale

Communiqués

12/09/12	Accentia Biopharmaceuticals Inc : Biovest Names Lymphoma Key Opinion Leader from MD Anderson Cancer Center to Scientific Advisory Board	PU
13/07/12	Accentia Biopharmaceuticals Inc : Biovest’s Eligibility to Seek EU Marketing Approval for its BiovaxID Cancer Vaccine as Orphan Drug Confirmed by EMA	PU
30/05/12	Accentia Biopharmaceuticals Inc : Biovest Names Dr. Eduardo Sotomayor, Chair of Dept of Malignant Hematology at Moffitt Cancer Center, to its Scientific Advisory Board	PU
19/05/12	Accentia Biopharmaceuticals Inc : Biovest Announces BiovaxID® ASCO Abstract Available On-line; NCI to Present Cancer Vaccine Data from Mantle Cell Lymphoma Study	PU
16/05/12	Accentia Biopharmaceuticals Inc : Biovest Retains Ferghana Partners to Evaluate Strategic Transactions	PU
04/05/12	Accentia Biopharmaceuticals Inc : Accentia Biopharmaceuticals Conducts Investigator Meeting in Preparation for New Multiple Sclerosis Drug Study for Cyrevia™	PU
23/04/12	Accentia Biopharmaceuticals Inc : Biovest and U.S. Army Enter into Collaborative Agreement to Develop Novel Bioreactor Systems as Platform Technology for Production of Anti-Viral Vaccines and Drugs	PU
20/04/12	Accentia Biopharmaceuticals Inc : Biovest Interviewed by OneMedRadio Regarding Global Regulatory Strategy to Seek Approvals for BiovaxID® Cancer Vaccine	PU
11/04/12	Accentia Biopharmaceuticals Inc : Biovest to Seek Marketing Approval for BiovaxID® Personalized Lymphoma Cancer Vaccine in Canada	PU
03/04/12	Accentia Biopharmaceuticals Inc : Biovest Announces International Members of its Cancer Vaccine Scientific Advisory Board	PU
27/03/12	Accentia Biopharmaceuticals Inc : Biovest Establishes World Class Scientific Advisory Board Comprised of Key Opinion Leaders in the Fields of Cancer Immunotherapy, Bioinformatics and Cell Culture Systems	PU
16/03/12	Accentia Biopharmaceuticals Inc : BiovaxID® Personalized Lymphoma Vaccine is Featured in Article Published in Drug Discovery News	PU
17/02/12	Accentia Biopharmaceuticals Inc : Biovest to Present on BiovaxID® Personalized Lymphoma Vaccine at San Francisco Cancer Biologics Conference	PU
06/02/12	Accentia Biopharmaceuticals Inc : BiovaxID® Personalized Lymphoma Vaccine is Featured in Article Published in HemOnc Today	PU
01/02/12	Accentia Biopharmaceuticals Inc : OneMedPlace Initiates Research Coverage on Biovest and BiovaxID® Personalized Lymphoma Vaccine	PU
20/01/12	Accentia Biopharmaceuticals Inc : Biovest Prepares for EU Regulatory Meetings; SME Status Granted Providing European Regulatory Benefits for BiovaxID Personalized Lymphoma Vaccine	PU
13/01/12	Accentia Biopharmaceuticals Inc : Biovest Collaborates with Max Planck Institute to Advance its Hollow Fiber Bioreactors for the Manufacture of Viral Vaccines	PU
10/01/12	Accentia Biopharmaceuticals Inc : Article Published on Fox News Website Predicts the Advance of Cancer Vaccines in 2012 including BiovaxID® Lymphoma Vaccine	PU
20/12/11	Accentia Biopharmaceuticals Inc : Accentia Biopharmaceuticals Completes Sale of Analytica Subsidiary	PU
20/12/11	Accentia Biopharmaceuticals Inc : BiovaxID® Lymphoma Vaccine is Featured in Article Published in Yale Journal of Biology and Medicine	PU
15/12/11	Accentia Biopharmaceuticals Inc : BiovaxID® Lymphoma Vaccine is Featured in Articles Published in Newsweek and Genetic Engineering & Biotechnology News	PU
14/12/11	Accentia Biopharmaceuticals Inc : BiovaxID® Lymphoma Vaccine-Induced T-Cell Immune Responses Complement Rituximab Induction Chemotherapy and Significantly Correlate with Overall Survival in Mantle Cell Lymphoma	PU
07/11/11	Accentia Biopharmaceuticals Inc : Accentia Biopharmaceuticals Announces Series of Agreements as Part of Debt Reduction Strategy to Strengthen Financial Condition, Improve Balance Sheet and Support Advancement of Immunotherapy Pipeline	PU
28/10/11	Accentia Biopharmaceuticals Inc : Biovest Announces that FDA Grants Orphan Drug Status for Personalized Cancer Vaccine for the Treatment of Waldenstrom’s Macroglobulinemia, a Rare Subtype of Non-Hodgkin’s Lymphoma	PU
07/10/11	Accentia Biopharmaceuticals Inc : Biovest Reports on Regulatory Strategy for Personalized Cancer Vaccine Targeting Non-Hodgkin’s Lymphoma	PU